Premium
O1‐06‐05: Polygenic Scoring for Risk Stratification of Future Cognitive Decline in Mild Cognitive Impairment (MCI)
Author(s) -
Shoai Maryam,
Escott-Price Valentina,
Pither Richard,
Davis Julie,
Laws Simon M.,
Hardy John
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.327
Subject(s) - disease , exome sequencing , cohort , snp , medicine , exome , polygenic risk score , set (abstract data type) , cognitive impairment , single nucleotide polymorphism , oncology , bioinformatics , biology , computer science , mutation , genetics , gene , genotype , programming language
tein up-regulated in AD EVs while 39 were down regulated with respect to the CTRL EVs. Up-regulated proteins in AD EVs were related to cell adhesion and motility, extracellular matrix remodeling and stress response, while down-regulated protein were associated with immune response and proteolysis. Overlap analysis with brain tissue proteomic data from pathologicallyconfirmed AD patients showed 8 protein candidates to be selected for validation. Conclusions: Proteomic analysis of CSF EVs may give an opportunity to sample pathologically linked brain-derived proteins in CSF. The establishment of EV isolation methods using clinically available CSF volumes is mandatory to perform biomarker validation. References: 1. Chiasserini D, et al., J Proteomics. 2014;106:191–204.